Drugs / IPN01203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07213830 | Feb 2026 → Jul 2032 expected | metastatic neoplasm | Ipsen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPN01203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213830 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT07213830 ↗ |